Reportlinker Adds Endometriosis - Drug Pipeline Analysis and Market Forecasts to 2016
NEW YORK, Feb. 9 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Endometriosis - Drug Pipeline Analysis and Market Forecasts to 2016
Endometriosis - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
GlobalData, the industry analysis specialist's new report, "Endometriosis - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global endometriosis market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global endometriosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global endometriosis sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The scope of the report includes:
- Annualized global endometriosis market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global endometriosis market. Key companies covered include Bayer AG, Pfizer, Aeterna Zentaris, Neurocrine Biosciences Inc., KV Pharmaceutical company.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with endometriosis.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global endometriosis market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global endometriosis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global endometriosis market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Endometriosis: Market Characterization 5
2.1 Overview 5
2.2 Endometriosis Market Size 5
2.3 Endometriosis Market Forecast and CAGR 6
2.4 Drivers and Barriers for Endometriosis Market 6
2.4.1 Drivers for Endometriosis Market 7
2.4.2 Barriers for Endometriosis Market 7
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Endometriosis Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Major Therapies in the Endometriosis Market 11
3.3.1 Non-steroidal anti-inflammatory drugs (NSAIDs) for Endometriosis 11
3.3.2 Gonadotropin-releasing hormone (GnRH) agonists for Endometriosis 11
3.3.3 Birth Control Hormones for Endometriosis 11
3.3.4 Progestins for Endometriosis 12
3.4 Key Takeaway 12
4 Endometriosis Market: Pipeline Assessment 13
4.1 Overview 13
4.2 Strategic Pipeline Assessment 13
4.2.1 Technology Trends Analytic Framework 13
4.3 Endometriosis Therapeutics – Promising Drugs Under Clinical Development 15
4.4 Molecule Profile for Promising Drugs under Clinical Development 16
4.4.1 Visanne 16
4.4.2 Proellex 16
4.4.3 Elagolix (NBI-56418) 17
4.4.4 MPI-676 18
4.5 Endometriosis Therapeutics Market – Clinical Pipeline by Therapeutic Class 18
4.6 Endometriosis Disease Pipeline – Pipeline by Clinical Phases of Development 19
4.6.1 Endometriosis Therapeutics – Phase III and Regulatory Filed Clinical Pipeline 20
4.6.2 Endometriosis Therapeutics – Phase II Clinical Pipeline 20
4.6.3 Endometriosis Therapeutics – Phase I Clinical Pipeline 21
4.6.4 Endometriosis Therapeutics – Preclinical Pipeline. 21
4.6.5 Endometriosis Therapeutics – Drug Discovery Pipeline 21
4.7 Key Takeaway 21
5 Global Endometriosis Market: Implications for Future Market Competition 22
6 Global Endometriosis Market: Future Players in Endometriosis Market 23
6.1 Introduction 23
6.2 Bayer AG 23
6.2.1 Company Overview 23
6.2.2 Business Description 24
6.3 Pfizer Inc. 25
6.3.1 Company Overview 25
6.3.2 Business Description 26
6.4 AEterna Zentaris Inc. 27
6.4.1 Company Overview 27
6.4.2 Business Description 28
6.5 Neurocrine Biosciences, Inc. 28
6.5.1 Company Overview 28
6.5.2 Business Description 29
6.6 KV Pharmaceutical Company 30
6.6.1 Company Overview 30
6.6.2 Business Description 30
7 Global Endometriosis Market: Appendix 32
7.1 Definitions 32
7.2 Acronyms 32
7.3 Research Methodology 32
7.3.1 Coverage 33
7.3.2 Secondary Research 33
7.3.3 Forecasting 34
7.3.4 Primary Research 37
7.3.5 Expert Panels 37
7.4 Contact Us 37
7.5 Disclaimer 37
7.6 Sources 38
1.1 List of Tables
Table 1: Global Endometriosis Market, Historic Revenue ($m), 2001-2009 6
Table 2: Global Endometriosis Market, Revenue Forecasts ($ m), 2009-2016 6
Table 3: Endometriosis Therapeutics – Most Promising Drugs Under Clinical Development, 2010 15
Table 4: Endometriosis Therapeutics – Phase III Clinical Pipeline, 2010 20
Table 5: Endometriosis Therapeutics – Phase II Clinical Pipeline, 2010 20
Table 6: Endometriosis Therapeutics – Phase I Clinical Pipeline, 2010 21
Table 7: Endometriosis Therapeutics – Preclinical Pipeline, 2010 21
Table 8: Endometriosis Therapeutics – Drug Discovery Pipeline, 2010 21
Table 9: Bayer AG – Women's Healthcare Pipeline Products, 2010 25
Table 10: Bayer AG – Endometriosis Pipeline Products, 2010 25
Table 11: Pfizer Inc – Women's Health Pipeline Products, 2010 27
Table 12: Pfizer Inc – Endometriosis Pipeline Products, 2010 27
Table 13: AEterna Zentaris Inc. – Women's Health Pipeline Products, 2010 28
Table 14: AEterna Zentaris Inc. – Endometriosis Pipeline Products, 2010 28
Table 15: Neurocrine Biosciences, Inc. – Women's Health Pipeline Products, 2010 29
Table 16: Neurocrine Biosciences, Inc. – Endometriosis Pipeline Products, 2010 29
Table 17: KV Pharmaceutical Company – Women's Health Pipeline Products, 2010 31
Table 18: KV Pharmaceutical Company – Endometriosis Pipeline Products, 2010 31
1.2 List of Figures
Figure 1: Global Endometriosis Market Forecasts ($m), 2001–2016 6
Figure 2: Endometriosis Market – Opportunity and Unmet Need, 2010 8
Figure 3: Endometriosis Market – Strategic Competitor Assessment, 2010 10
Figure 4: Technology Trends Analytic Framework of the Endometriosis Pipeline, 2010 13
Figure 5: Technology Trends Analytic Framework of the Endometriosis Pipeline – Description, 2010 14
Figure 6: Endometriosis Market – Clinical Pipeline by Mechanism Of Action, 2010 19
Figure 7: Endometriosis Pipeline by Phase of Clinical Development, 2010 19
Figure 8: Endometriosis Therapeutics Market – Strategic Competitor Assessment, 2010 22
Figure 9: Endometriosis Therapeutics Market – Clinical Pipeline by Company, 2010 23
Figure 10: GlobalData Methodology 33
Figure 11: GlobalData Market Forecasting Model 36
Companies Mentioned
Bayer AG
Pfizer Inc.
AEterna Zentaris Inc
Neurocrine Biosciences, Inc
KV Pharmaceutical Company
To order this report:
Drug and Medication Industry: Endometriosis - Drug Pipeline Analysis and Market Forecasts to 2016
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article